Highlights Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Market Closed - Nasdaq Other stock markets 02:00:01 18/05/2024 am IST			5-day change	1st Jan Change
4.49 ^USD	+4.42%		+9.51%	-65.31%

16/04	Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
11/04	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Reverse Split: 1 of 18	22/04	FA
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
North American Morning Briefing : Stock Futures -2-	11/04	DJ
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals	09/04	MT
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.	08/04	CI
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research	01/02	CI
Windtree Therapeutics, Inc. Enters into License, Development and Commercialization Agreement with Lee?s Pharmaceutical (HK) Ltd	17/01	CI
Windtree Therapeutics, Inc. Announces Reduction in Arrythmias in a New Study With Istaroxime And A Pure SERCA2a Activator	03/01	CI
Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock	18/12	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Windtree Therapeutics Secures US Patent Covering Product Candidates Aimed to Treat Heart Failure Patients	23/23/23	MT
Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators	16/23/16	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Windtree Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement	13/23/13	MT
Windtree Therapeutics, Inc. Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure	28/23/28	CI
Windtree Therapeutics Secures New Patent for Experimental Heart Failure Drug Candidate	24/23/24	MT
Reverse Split: 1 of 50	24/23/24	FA
Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Windtree Therapeutics, Inc.

Equities

WINT

US97382D5014

Highlights

Filters